Mast Therapeutics, Inc. (NYSEMKT:MSTX)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases.

Recs

0
Player Avatar pchop123 (76.57) Submitted: 7/9/2012 12:43:30 PM : Outperform Start Price: $0.60 MSTX Score: +22.50

ripe for some nice upside now

Featured Broker Partners


Advertisement